These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6255896)

  • 1. Immunogenicity of subviral herpes simplex virus type 1 preparation: protection of mice against intradermal challenge with type 1 and type 2 viruses.
    Slichtová V; Kutinová L; Vonka V
    Arch Virol; 1980; 66(3):207-14. PubMed ID: 6255896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subviral herpes simplex vaccine.
    Kutinovà L; Slichtová V; Vonka V
    Dev Biol Stand; 1982; 52():313-9. PubMed ID: 6299840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of subviral herpes simplex virus preparations: protection of mice against intraperitoneal infection with live virus.
    Kutinová L; Vonka V; Slichtová V
    Acta Virol; 1980 Dec; 24(6):391-8. PubMed ID: 6111199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of a subviral herpes simplex type 1 preparation: reduction of recurrent disease in mice.
    Slichtová V; Kutinová L; Vonka V
    Arch Virol; 1982; 71(1):75-8. PubMed ID: 6279057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of purified glycoprotein gB of herpes simplex virus.
    Kino Y; Eto T; Nishiyama K; Ohtomo N; Mori R
    Arch Virol; 1986; 89(1-4):69-80. PubMed ID: 3013134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.
    Klein RJ; Buimovici-Klein E; Moser H; Moucha R; Hilfenhaus J
    Arch Virol; 1981; 68(2):73-80. PubMed ID: 6264897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protectivity of herpes simplex virus antigens: studies in mice on the adjuvant effect of PICLC and on the dependence of protection on T cell competence.
    Hilfenhaus J; Christ H; Köhler R; Moser H; Kirchner H; Levy HB
    Med Microbiol Immunol; 1981; 169(4):225-35. PubMed ID: 6268955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restriction of latent herpes virus infection in rabbits immunized with subviral herpes simplex virus vaccine.
    Rajcáni J; Kutinová L; Vonka V
    Acta Virol; 1980 May; 24(3):183-93. PubMed ID: 6107035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
    Weinberg A; Merigan TC
    J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of in vivo depletion of immunocyte populations on herpes simplex virus glycoprotein D vaccine-induced resistance to HSV2 challenge.
    Mishkin EM; Blasiak M; Giorgio D; Ishizaka ST
    Viral Immunol; 1992; 5(2):151-61. PubMed ID: 1319710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
    Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
    Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of herpes simplex virus in congenitally athymic mice: the relative roles of cell-mediated and humoral immunity.
    Kapoor AK; Nash AA; Wildy P; Phelan J; McLean CS; Field HJ
    J Gen Virol; 1982 Jun; 60(Pt 2):225-33. PubMed ID: 6286849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted.
    Farrell HE; McLean CS; Harley C; Efstathiou S; Inglis S; Minson AC
    J Virol; 1994 Feb; 68(2):927-32. PubMed ID: 8289395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.
    Cremer KJ; Mackett M; Wohlenberg C; Notkins AL; Moss B
    Science; 1985 May; 228(4700):737-40. PubMed ID: 2986288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat-shock protein 70 acts as an effective adjuvant in neonatal mice and confers protection against challenge with herpes simplex virus.
    Pack CD; Kumaraguru U; Suvas S; Rouse BT
    Vaccine; 2005 May; 23(27):3526-34. PubMed ID: 15855011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
    Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
    Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models.
    Mishkin EM; Fahey JR; Kino Y; Klein RJ; Abramovitz AS; Mento SJ
    Vaccine; 1991 Mar; 9(3):147-53. PubMed ID: 1645898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine.
    Kitces EN; Morahan PS; Tew JG; Murray BK
    Infect Immun; 1977 Jun; 16(3):955-60. PubMed ID: 197013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute and recurrent infection with herpes simplex virus in the mouse: a model for studying latency and recurrent disease.
    Hill TJ; Field HJ; Blyth WA
    J Gen Virol; 1975 Sep; 28(3):341-53. PubMed ID: 170376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and protective efficacy in a rhesus monkey model of vaccine Ac NFUi(S-) MRC against primary type 2 herpes simplex virus infection.
    Skinner GR; Buchan A; Williams D; Marsden J; Hartley C; Wilbanks G; Turyk M; Namkoong ES
    Br J Exp Pathol; 1982 Aug; 63(4):378-87. PubMed ID: 6295430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.